Cargando…
Chronic Myeloid Leukemia Patients in Prolonged Remission following Interferon-α Monotherapy Have Distinct Cytokine and Oligoclonal Lymphocyte Profile
Before the era of tyrosine kinase inhibitors (TKIs), interferon-alpha (IFN-α) was the treatment of choice in chronic myeloid leukemia (CML). Curiously, some IFN-α treated patients were able to discontinue therapy without disease progression. The aim of this project was to study the immunomodulatory...
Autores principales: | Kreutzman, Anna, Rohon, Peter, Faber, Edgar, Indrak, Karel, Juvonen, Vesa, Kairisto, Veli, Voglová, Jaroslava, Sinisalo, Marjatta, Flochová, Emília, Vakkila, Jukka, Arstila, Petteri, Porkka, Kimmo, Mustjoki, Satu |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2011
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3153480/ https://www.ncbi.nlm.nih.gov/pubmed/21857985 http://dx.doi.org/10.1371/journal.pone.0023022 |
Ejemplares similares
-
Enlarged Memory T-Cell Pool and Enhanced Th1-Type Responses in Chronic Myeloid Leukemia Patients Who Have Successfully Discontinued IFN-α Monotherapy
por: Ilander, Mette, et al.
Publicado: (2014) -
Dasatinib promotes Th1-type responses in granzyme B expressing T-cells
por: Kreutzman, Anna, et al.
Publicado: (2014) -
Immune cell constitution in bone marrow microenvironment predicts outcome in adult ALL
por: Hohtari, Helena, et al.
Publicado: (2019) -
Early BCR-ABL1 Transcript Decline after 1 Month of Tyrosine Kinase Inhibitor Therapy as an Indicator for Treatment Response in Chronic Myeloid Leukemia
por: El Missiry, Mohamed, et al.
Publicado: (2017) -
Copy number alterations define outcome in Philadelphia chromosome-positive acute lymphoblastic leukemia
por: Hohtari, Helena, et al.
Publicado: (2022)